Head-to-head · WeighScore
Edessa vs YourHealthRx
The verdict
Edessa takes it — 70.8/100 to 69.6/100, but only just.
Edessa grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Clean three-rung tables one click in, behind a homepage whose three cards all quote six-month rungs and whose cheapest belongs to a different drug. YourHealthRx is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Edessa | YourHealthRx |
|---|---|---|
| WeighScore | 70.8/100 | 69.6/100 |
| Grade | C | C |
| Scorecard rank | #115 | #137 |
| Semaglutide | $179/mo month-to-month injectable ($135 only on a 6-month prepay) | $170/mo (compounded) |
| Tirzepatide | $239/mo month-to-month ($209 only on a 6-month prepay) | $210/mo (compounded) |
| Coverage | Not publicly listed | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
Graded #115 · C
Strengths
- Each product page carries a plain three-rung table, so the commitment behind every figure is visible
- "Same price, every dose" is printed on each product page
- Names its operating entity and a full street address in Las Vegas, Nevada
- All-inclusive: provider consultation, medication, free expedited shipping, ongoing check-ins and 24/7 clinical support, and HSA and FSA eligible
- An oral tablet sits beside the two injections
Where it loses points
- The homepage leads with "Start for just $135", a six-month prepay on the semaglutide injection; month-to-month tirzepatide is $239
- All three homepage cards quote the six-month rung, so the real monthly rates appear only after a click
- Its Terms give two corporate forms for the same company in one clause — "Edessa Group, LLC, a Nevada corporation"
- "Join 100,000+ successful GLP-1 patients" carries no source, and the money-back guarantee's terms are on no marketing page
- No lab or monitoring protocol is published
Graded #137 · C
Strengths
- Available in all 50 states and DC through a multi-state (IMLC) licensed clinician network
- Compounded semaglutide and tirzepatide in two formats - weekly injectable (with B12) or daily oral dissolving tablet
- Flat subscription price that doesn't change as your dose increases (no titration penalty)
- Science-forward, clinician-led, with built-in follow-up, lab testing, and a broad peptide and longevity catalog (BPC-157, TB-500, sermorelin, NAD+)
- Transparent, education-first positioning with published medical disclaimer, privacy, and terms
Where it loses points
- Eligibility and prescribing run through partner clinical workflows - YourHealthRx is the platform, not the prescriber or pharmacy
- Compounded medications are not FDA-approved - not brand Wegovy, Ozempic, Zepbound, or Mounjaro
- The compounding pharmacy partner is not named ('transparent sourcing' claimed but no pharmacy disclosed)
- Headline prices include a first-month intro rate; ongoing monthly cost is higher (semaglutide ~$170, tirzepatide ~$210)
- No LegitScript certification displayed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 544 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.